Septerna, Inc.

NASDAQ:SEPN

Biotechnology

Healthcare
$39.45 -2.04%

-$0.73 today

Market cap
$1.88B
Beta
2.38
P/E (TTM)
-43.6
EPS (TTM)
-$0.81
52W Low $9.96High $37.32

Volume 0.30M

Average 0.32M

SEPN Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Septerna, Inc.NASDAQ: SEPN

Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026

Other income / expenses dips below year-ago levels

Q3 FY2026 other income / expenses of $5.26M fell 5.4% year over year, behind the +12.8% change in trailing-twelve-month other income / expenses. Sequentially, it rose 10.2% from the prior quarter.

Context

  • Other income / expenses amounted to 69.5% of revenue in FY2025, down 723.7 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly growth recovers from -5.4% toward the trailing-twelve-month pace of +12.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$5.26M+10.2% QoQ
Last fiscal yearDec 2025
$31.93M+274.5% YoY
LTMSep 2026
$20.33M+12.8% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.4%——
1 year+274.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
31.93M USD
Year-over-year change
+274.5%
2-year CAGR
+237.9%

Other Income / Expenses vs competitors

How SEPN compares with its peers on the latest reported figures

  • SEPN's LTM Sep 2026 other income / expenses of $20.33M is the 3rd highest of the 7 companies compared; the peer median is $13.37M.
  • Its year-over-year change of +12.8% is the 4th highest of 6, against a peer median of +46.9%.
  • Other income / expenses amounts to 21.1% of revenue for SEPN, versus a peer median of 31.9%.
SEPN Competitors Peer median
Other Income / Expenses for SEPN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$43.71M +6.2%+388.5%—
BMEABiomea Fusion, Inc.LTM Mar 2026$21.62M +427.9%+121.1%—
SEPNSepterna, Inc.LTM Sep 2026$20.33M +12.8%—21.1%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$15.24M +46.9%——
MAZEMaze Therapeutics, Inc.LTM Mar 2026$11.51M +295.2%—57.5%
KLRAKailera Therapeutics, Inc.FY2025$9.39M ———
VTVTvTv Therapeutics Inc.LTM Mar 2026$2.31M +7.4%—6.3%
Peer median (excluding SEPN) $13.37M+46.9%+254.8%31.9%

Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue151K1.08M45.95M
Cost of Revenue000
Gross Profit151K1.08M45.95M
Gross Margin100.0%100.0%100.0%
Research & Development35.98M65.34M97.58M
Selling, General & Admin9.72M16.56M29.16M
Operating Expenses(1.92M)81.9M126.75M
Depreciation & Amortization848K1.4M1.6M
EBITDA(44.7M)(70.9M)(47.26M)
EBITDA Margin-29604.0%-6594.9%-102.9%
Operating Income2.08M(80.82M)(80.8M)
Operating Margin1374.2%-7518.4%-175.8%
Interest Income2.79M8.62M19.53M
Interest Expense000
Other Income / Expenses2.8M8.53M31.93M
Income Before Tax4.87M(72.3M)(48.87M)
Pre-Tax Margin3225.8%-6725.2%-106.3%
Income Tax Expense691K(498K)12K
Net Income4.18M(71.8M)(48.88M)
Net Margin2768.2%-6678.9%-106.4%
EPS (Basic)0.03(1.93)(1.10)
EPS (Diluted)0.03(1.93)(1.10)
Weighted Avg Shares19.5M37.19M44.26M
Weighted Avg Shares (Diluted)19.5M37.19M44.26M

Septerna, Inc.

NASDAQ:SEPN

Intrinsic Alpha fair value

Locked

Current Price

$39.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.